Oncology Adjuvants

Technologies and Global Markets

Product Code BCC00373
Publication Date August 2010
Publisher BCC Research
Product Type Report
Pages 126
ISBN Number not applicable
Change currency
PDF £3,065.00 €3,691 $4,847 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Oncology Adjuvants

Technologies and Global Markets

This report covers the current status of the global oncolytic adjuvant marketplace and assess its growth potential over the five-year period from 2010 to 2015.

Highlights:

  • The global human oncology adjuvants market was valued at $45.1 billion in 2009. This market is expected to reach $53 billion in 2010 and $91.7 billion in 2015, a compound annual growth rate (CAGR) of 11.6%
  • Breast cancer represents 28.9% of oncology adjuvant sales. This segment was worth $13 billion in 2009 and $13.7 billion in 2010 and will increase at a 9% compound annual growth rate (CAGR) to reach a value of nearly $21 billion in 2015.
  • The fastest area of sales growth overall is in the colorectal cancer space with a 16.1% compound annual growth rate (CAGR) forecast from the period of 2010 to 2015. This segment was worth $5.2 billion in 2009 and is expected to reach $8.7 billion in 2010 and $18.3 billion in 2015.

Study Goals and Objectives

BCC's goal in conducting this study was to determine the current status of the global oncolytic adjuvant marketplace and assess its growth potential over the five-year period from 2010 to 2015. We were particularly interested in approved oncology adjuvants and those that are late phase in the development pipeline. We have limited the scope of this report to the 30 Food and Drug Administration (FDA)- approved oncology adjuvants with antitumor or tissue protective activity. These therapies include the following product types@@# pharmaceuticals, immunotherapy, and radiosensitizing/radioprotective adjuvants.

Our key objective with this report is to produce an intensive analysis of the current oncology adjuvant marketplace in prostate, breast, and lung cancers, and to explore its future direction. In addition, we have included a detailed current review of other cancer indications, including colorectal, leukemias, lymphomas, digestive, urinary/reproductive systems, cutaneous, and other organ-based cancers.

We have specifically excluded a detailed analysis of medical devices; adjuvants to surgery; and other nonradiopharmaceutical, nonbiologic, nonnatural/herbal, nonpharmaceutical, nonbiologic therapies, though on occasion there may be limited discussion of significant developments. There is a limited discussion of preventive and therapeutic vaccines, which are FDA-approved in preneoplastic conditions such as human papillomavirus (HPV).

Reasons for doing this study

Cancerous and malignant tumors, particularly those that are in an advanced state, often are incurable and recurrent. Their etiologies are based on a host of factors ranging from genetics, radiation exposure, exposure to a chemical and/or biological carcinogen, and lifestyle factors, or any combination of the above. To further complicate treatment, there are issues of drug resistance, proper early diagnosis, and reoccurrence of the disease, while keeping the host healthy during treament. As such, BCC was particularly interested in examining the oncology market of adjunctive therapies administered with traditional oncology treatments, which are the cutting edge of development in oncolytics.

Intended Audience

This report was prepared as a study of the global oncolytic adjuvant marketplace based on data of incidence and morality of selected cancer indications with a focus on human therapeutics. Information is presented on the oncology industry in general, including a focus on the adjuvants market segment including chemotherapies, immunotherapies, radiotherapeutics, and natural therapeutics that may enhance a medicinal or radiation therapy of a form of cancer; new technologies; new and novel drug applications; market-related issues; and in many cases actual revenue as displayed for the period of 2007 to 2009, with projections of trends and compound annual growth rates (CAGRs) through 2015.

This study will be of significant interest to hospitals, pharmacies, pharmaceutical companies, biopharmaceutical researchers, pharmaceutical company marketing executives, contract research organizations (CROs), chemists, physicians, nurses, physician assistants, pharmaceutical directors, product managers and representatives, and all manner of institutional directors ranging from nursing homes and schools, to those in long-term-care situations, both public and private. It will also be of interest to investment bankers in the biotechnology and pharmaceutical sectors, insurance executives, and oncology product marketing managers.

Scope of Report

This study examines the human applications both marketed and in development of adjuvant technologies in oncology. In extensive analysis, BCC analyzes each market segment, presents its current market status and presents various forecasts for growth over the next 5 years. Other factors, such as FDA restrictions, government legislation, a cancer's drug resistance to therapeutics, and/or natural and alternative remedies are also highlighted. Our financial and sales analysis focuses on the available figures from 2007 to 2009, with estimates for the years 2010 to 2015, including CAGR as a percentage.

Methodology

Both primary and secondary research methodologies were used in preparing this report. Through an extensive industry survey, inclusive of online database searches of industry-specific data sources, coupled with financial, trade, government, and marketing database sources, as well as interviews via correspondence or telephone with independent sources comprising companies, government agencies, and academic experts, BCC was able to compile data to present our analysis of the oncology adjuvant market, by market segment.

Information Sources

Of the companies and agencies surveyed, the majority were pharmaceutical or compound manufacturers. Additional information was supplied by known industry or trade sources.

Analyst Credentials

Michael Delander is a biotechnology research consultant with more than 15 years of research experience. Michael has been consulting with venture capital-based start-ups and larger industry players since 2003, and has focused on in-depth research in a wide range of medical therapeutics in early development. His key published work is located in national and international organizations, including the National Library of Medicine, numerous Ivy League libraries, and the University of California.

Contents

  • Chapter One: Introduction
    • Study Goals and Objectives
    • Reasons for Doing This Study
    • Intended Audience
    • Scope of Report
    • Methodology
    • Information Sources
    • Analyst Credentials
    • Related Bcc Reports
    • Bcc Online Services
    • Disclaimer
  • Chapter Two: Summary
    • Summary
    • Summary Table Global Market forecast for Oncology Adjuvants, through 2015 ($ Millions)
    • Summary Figure Global Oncology Adjuvant Sales by Market Geography, 2009 and 2015 (%)
  • Chapter Three: Overview
    • History and Current State of Oncology and Concepts of Adjuvants in Oncology
    • Types of Cancer
    • Definition of the Industry
    • Importance of the Industry
    • Product Life Cycles
    • Table 1 Drug Development Lifecycle Following
    • Discovery of New Drug
    • Development of Oncology Adjuvants
    • Table 2 Historical Pipeline of Fda-Approved Oncology Adjuvants
    • Human Clinical Development
    • New Drug Activity
    • Future Developments
    • 2008 To 2009 Drug Activity
    • 2008 To 2009 Drug Activity (Continued)
    • With An Eye Toward the Future
  • Chapter Four: Type of Applications in the Human
    • Oncology Adjuvant Marketplace: Chemotherapy, Immunotherapy, and Radiotherapy
    • Table 3 Global Market forecast for Oncology Adjuvants Sales by Product Type, through 2015 ($ Millions)
    • Figure 1 Oncology Adjuvants Sales: by Adjunctive Product Type, 2008-2015 ($ Millions)
  • Chapter Five: Human Cancers
    • Table 4 Global Market forecast for Oncology Adjuvants by Cancer Indication, through 2015 ($ Millions)
    • Figure 2 Oncology Adjuvants forecast Sales: by Type of Cancer 2008-2015 ($ Millions)
    • Risk Factors for Developing Cancers
    • Table 5 Risk Factors Associated With Human Cancer
    • Table 6 Incidence Associated With Human Cancers in Men
    • Table 7 Incidence Associated With Human Cancers in Women
    • Table 8 Human Cancer Trends, Estimated, 2008-2015 (Number of Cases)
    • Breast
    • Table 9 Global Sales forecast of Breast Cancer Oncology Adjuvants by Geography, through 2015 ($ Millions)
    • Rectum and Colon
    • Table 10 Global Sales forecast of Colorectal Cancer Adjuvants by Geography, through 2015 ($ Millions)
    • Non-Hodgkin Lymphomas
    • Table 11 Global Sales forecast of Lymphomas Adjuvants by Georgraphygeography, through 2015 ($ Millions)
    • Lung
    • Table 12 Global Sales forecast of Lung Cancer Adjuvants by Geography, through 2015 ($ Millions)
    • Leukemia
    • Table 13 Global Sales forecast of Leukemia Adjuvants by Geography, through 2015 ($ Millions)
    • Prostate Cancer
    • Table 14 Global Sales forecast of Prostate Cancer Adjuvants by Geography, through 2015 ($ Millions)
    • Glioblastoma
    • Table 15 Global Sales forecast of Glioblastoma Adjuvants by Geography, through 2015 ($ Millions)
    • Multiple Myeloma
    • Table 16 Global Sales forecast of Multiple Myeloma Adjuvants by Geography, through 2015 ($ Millions)
    • Gastric
    • Table 17 Global Sales forecast of Gastric Cancer Adjuvants by Geography, through 2015 ($ Millions)
    • Table 18 Global Sales forecast of All Other Oncology Adjuvants Sales by Geography, through 2015 ($ Millions)
    • Kidney
    • Ovary
    • Pancreas
    • Urinary Bladder
    • Uterine Cervix
    • Skin Cancer
    • Tumor Types and Stages
    • Table 19 Adjuvants Utilized by Stage of Cancer by Indication
    • Table 20 Side Effects of Adjuvant therapeutics
    • Chapter Six: Human Oncology Adjuvants
    • Table 21 Global Sales forecast of Oncology Adjuvants Consumption by Branded Vs. Generic All Product Types of Adjuvants, through 2015 ($ Millions)
    • Figure 3 Global Sales forecast of Oncology Adjuvants Consumption by Branded Vs. Generic All Product Types of Adjuvants, 2008-2015 ($ Millions)
    • Chemotherapies
    • Table 22 Global Sales forecast of Chemotherapies by Cancer Indication, through 2015 ($ Millions)
    • Figure 4 Global Sales forecast of Chemotherapies by Cancer Indication, 2008-2015 ($ Millions)
    • Table 23 Global Sales forecast of Branded Vs. Generic Chemotherapies, through 2015 ($ Millions)
    • Immunotherapies
    • Table 24 Global Sales forecast of Immunotherapies by Cancer Indication, through 2015 ($ Millions)
    • Figure 5 Global Sales forecast of Immunotherapies by Cancer Indication, through 2008-2015 ($ Millions)
    • Table 25 Global Sales forecast of Branded Vs. Generic Immunotherapies, through 2015 ($ Millions)
    • Radiotherapeutics
    • Table 26 Global Sales forecast of Branded Vs. Generic Radiotherapies, through 2015 ($ Millions)
    • Figure 6 Global Sales forecast of Radiotherapeutics By Cancer Branded and Generic, 2008-2015 ($ Millions)
    • Other
    • Table 27 Global Sales forecast for Generic Oncology Adjuvants Chemotherapies and Radiotherapies, through 2015 ($ Millions)
    • Figure 7 Global Sales forecast of Generic Oncology Adjuvants Chemotherapies and Radiotherapies, 2008-2015 ($ Millions)
    • Table 28 Global Sales forecast of Generic Oncology Adjuvants Broken Down by Cancer Indication, through 2015 ($ Millions)
    • Figure 8 Global Sales forecast of Generic Oncology Adjuvants by Cancer Indication, 2008-2015 ($ Millions)
    • Table 29 Global Sales forecast of Chemotherapeutics Broken Down by Geography, through 2015 ($ Millions)
    • Table 30 Global Sales forecast of Immunotherapies Broken Down by Geography, through 2015 ($ Millions)
    • Table 31 Global Sales forecast of Radiotherapies Broken Down by Geography, through 2015 ($ Millions)
    • Table 32 Global Sales forecast of Oncology Adjuvants By Routes of Administration, through 2015 ($ Millions)
    • Figure 9 Global Sales forecast of Oncology Adjuvants By Routes of Administration, 2008-2015 ($ Millions)
    • Table 33 List of Chemotherapies and their Adjuvants and for Which Cancer they Are Indicated
    • Treatment Cost Data
    • Table 34 Price of Major Oncology Adjuvants by Combination in Price Per Month Most Current Data, 2005-2006 ($)
  • Chapter Seven: Traditional Medicines
    • A Brief History of Natural Medicines
    • More Current Fda Approvals of Natural Medicines
    • Natural Products in Clinical Trials
    • Table 35 Natural Agents With References To Clinical Trials
    • Selected Summaries of Herbal/Natural Adjuvants
    • That Are Not Listed in Clinical Databases
    • Table 36 Other Traditional therapies Not Listed in Clinical Trials Databases
    • Table 37 Common Herbal Oncology Adjuvants
  • Chapter Eight: Government Regulatory Agencies and Professional Associations
    • Food and Drug Administration
    • Food and Drug Administration (Continued)
    • Table 38 Oncology Adjuvant Warning Letters for the Human Segment From the Fda: 1997-2009
    • Environmental Protection Agency (Epa)
    • Professional Associations
    • American Association for Cancer Research
    • American Society of Clinical Oncology: Asco
  • Chapter Nine: Major Oncology Adjuvants Manufacturers
    • Major Branded Manufacturers
    • Table 39 Major Oncology Adjuvant Human
    • Pharmaceutical Manufacturers
    • Figure 10 Percentage of Oncology Adjuvant
    • Pharmaceutical Manufacturers by Country (%)
    • Table 40 Major Pharmaceutical Oncology Adjuvant Manufacturers, 2009 ($ Billions)
    • Major Pharmaceutical Manufacturer Profiles
    • Abraxis Bioscience Corporate Headquarters
    • Amgen Inc
    • Astrazeneca Plc
    • Biogen
    • Bms
    • Celgene Corporation
    • Enzon Pharmaceuticals, Inc
    • Genentech, Inc
    • Gsk
    • Merck
    • Eli Lilly Co
    • Novartis
    • Osi Pharmaceuticals, Inc
    • Sanofi-Aventis
    • Pfizer, Inc
    • F. Hoffmann-La Roche Ltd
    • Valeant
    • Generic Market
    • Table 41 Major Generic Oncology Adjuvants Manufacturers and Products
    • Generic Pharmaceutical Manufacturer Profiles
    • Accord Healthcare Inc
    • Actavis Totowa
    • Bedford Laboratories
    • Fresenius Kabi Oncology
    • Hospira, Inc
    • Stason Pharmaceuticals, Inc
    • Sun Pharma Indus Ltd
    • Teva Pharmaceutical Industries Ltd
    • Watson Labs
    • Traditional/Alternative Medicine Manufacturer
    • Profiles
    • Table 42 Commonly Available Alternative Oncology Adjuvants
    • American formulary, Inc
    • American Biologics
    • Bluebonnet Nutrition Corp
    • Cvc4health.Com
    • Country Life, Llc
    • Enzymatic therapy, Inc
    • Foodscience of Vermont
    • Herbasway
    • Life Extension Foundation
    • Nature's Answer
    • Premier Research Labs
  • Chapter Ten: Oncology Adjuvants Industry
    • Oncology Adjuvant Market Trends: Human
    • Healthcare
    • Accelerating Oncology Adjuvant Drug Development
    • Breast Cancer
    • Colorectal Cancer
    • Sarcoma
    • Glioblastoma
    • Hodgkin's Lymphoma
    • Lung
    • Ovarian
    • Prostate
    • Table 43 Pharmaceutical Oncology Adjuvants Products in the Pipeline, 2009
    • Table 44 New Prescription Oncology Adjuvants through 2009
    • Need To Increase Use and Acceptance of Newer Drugs
    • Need To Increase Use and Acceptance ... (Continued)
  • Chapter Eleven: Patent Analysis
    • Purpose of A Patent Analysis
    • Due Care in Reviewing the Patent Analysis
    • New Oncology Adjuvants Patents Issued
    • Table 45 Oncology Adjuvant Patent Trends, 1990-2010
    • Oncology Adjuvant Patent Trends, 1990-2009
    • Table 46 Patents by Oncology Adjuvant - therapy Type, 1990-2009
    • Table 47 New Oncology Adjuvants Patents Issued, 2008-2009
    • Table 48 Assignees of Two Or More Patents for Oncology Adjuvant Products, 2008 Through 2009
    • Table 49 Patent Trends by Country, 2008-2009
    • Figure 11 New Oncology Adjuvant Patent Approvals by Country, 2008-2009 (%)
    • Trends in Patent Applications
    • Table 50 Total Oncology Adjuvant Patent Application Trends, 2001-2009
    • Figure 12 Oncology Adjuvant Patent Applications by Year, 2001-2009 (%)
    • Table 51 Patent Applications by Oncology Adjuvant therapy Type, 2008-2009
    • Figure 13 Percentage of Patent Applications by Oncology Adjuvant therapy Type, 2008-2009 (%)
    • Table 52 New Patent Applications, 2008 Through 2009
    • Table 53 Patent Application Trends by Country, 2008-2009
    • Figure 14 Oncology Adjuvant Patent Applications by Country, 2008-2009 (%)
    • Patent Expirations
    • Table 54 Patent Expirations, 2006-2011
    • Table 55 Pharmaceutical Companies